Group 1 - The core point of the announcement is the adjustment of the conversion price for the company's convertible bonds "Kangtai Zhuan 2" from 15.82 CNY to 15.73 CNY per share, effective from June 6, 2025 [1][2] - The adjustment is based on the company's 2024 annual equity distribution plan, which includes a cash dividend of 0.90 CNY per 10 shares, with no stock dividends or capital reserve transfers [2] - The adjustment formula used for the conversion price is P1 = P0 - D, where P0 is the previous conversion price and D is the cash dividend per share [2] Group 2 - The company issued 20 million convertible bonds on July 15, 2021, under the code "Kangtai Zhuan 2" [1] - The adjustment of the conversion price is in accordance with relevant laws and regulations, as well as the terms outlined in the bond issuance prospectus [1][2] - The effective date for the new conversion price will be the day after the equity distribution, which is June 6, 2025 [2]

证券代码：300601 证券简称：康泰生物 公告编号：2025-050 债券代码：123119 债券简称：康泰转 2 深圳康泰生物制品股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 一、股东大会审议通过利润分配方案情况 分派方案已经公司 2025 年 5 月 20 日召开的 2024 年度股东大会审议通过。2024 年度利润分配方案为：以 2024 年年度权益分派实施公告中确定的股权登记日当 日的总股本为基数，向全体股东每 10 股派 0.90 元（含税）现金红利，不送红股， 不以资本公积金转增股本。 事项发生变化。根据公司 2024 年度股东大会决议，本次权益分派以 2024 年年度 权益分派实施公告中确定的股权登记日当日的总股本为基数，无需调整分配比例， 公司按照分配比例不变的原则对分配总额进行调整。 原则一致。 二、本次实施的利润分配方案 公司 2024 年年度权益分派方案为：以 2024 年年度权益分派实施公告中确定 的股权登记日当日的总股本为基数，向全体股东每 10 股派 0.900000 元现金红利 （含税；扣税后，通过深股通持有股份 ...

| | | 证券代码：300601 证券简称：康泰生物 公告编号：2025-051 债券代码：123119 债券简称：康泰转 2 深圳康泰生物制品股份有限公司 关于可转债转股价格调整的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 特别提示： 债券代码：123119 债券简称：康泰转 2 调整前"康泰转 2"转股价格为：15.82 元/股 调整后"康泰转 2"转股价格为：15.73 元/股 转股价格调整生效日期：2025 年 6 月 6 日 一、可转换公司债券转股价格调整依据 深圳康泰生物制品股份有限公司（以下简称"公司"）于 2021 年 7 月 15 日 向不特定对象发行了 2,000.00 万张可转换公司债券（债券简称：康泰转 2，债 券代码：123119）。根据相关法律法规和《深圳康泰生物制品股份有限公司向不 特定对象发行可转换公司债券募集说明书》（以下简称"募集说明书"）的相关规 定，在本次"康泰转 2"发行之后，当公司发生派送股票股利、转增股本、增发 新股（不包括因本次发行的可转债转股而增加的股本）、配股以及派发现金股利 等情况时，公司将按上 ...

证券代码：300601 证券简称：康泰生物 公告编号：2025-050 深圳康泰生物制品股份有限公司 2024 年年度权益分派实施公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 债券代码：123119 债券简称：康泰转 2 一、股东大会审议通过利润分配方案情况 1、深圳康泰生物制品股份有限公司（以下简称"公司"）2024 年年度权益 分派方案已经公司 2025 年 5 月 20 日召开的 2024 年度股东大会审议通过。2024 年度利润分配方案为：以 2024 年年度权益分派实施公告中确定的股权登记日当 日的总股本为基数，向全体股东每 10 股派 0.90 元（含税）现金红利，不送红股， 不以资本公积金转增股本。 2、本次权益分派方案自披露至实施期间，公司股本总额可能因可转债转股 事项发生变化。根据公司 2024 年度股东大会决议，本次权益分派以 2024 年年度 权益分派实施公告中确定的股权登记日当日的总股本为基数，无需调整分配比例， 公司按照分配比例不变的原则对分配总额进行调整。 3、本次实施的权益分派方案与股东大会审议通过的权益分派方案及其调整 ...

北京│上海│深圳│杭州│广州│昆明│天津│成都│宁波│福州│西安│南京│南宁│济南│重庆│苏州│长沙│太原│武汉│贵阳│乌鲁木齐│郑州│石家庄│合肥│ 海南│青岛│南昌│大连│银川│拉孜│香港│巴黎│马德里│斯德哥尔摩│纽约│马来西亚│柬埔寨 BEIJING│SHANGHAI│SHENZHEN│HANGZHOU│GUANGZHOU│KUNMING│TIANJIN│CHENGDU│NINGBO│FUZHOU│XI'AN│NANJING│NANNING│JINAN│CHONGQING│SUZHOU│CHANGSHA│AIYUAN│WUHAN│GUIYANG│URUMQI│ ZHENGZHOU│SHIJIAZHUANG│HEFEI│HAINAN│QINGDAO│NANCHANG│DALIAN│YINCHUAN│LHATSE│HONG KONG│PARIS│MADRID│STOCKHOLM│NEW YORK│MALAYSIA│Cambodia 国浩律师（深圳）事务所 关于 深圳康泰生物制品股份有限公司 2024 年度股东大会 之 法律意见书 GLG/SZ/A4303/FY/2025-533 致：深圳康泰生物制品股份有 ...

| 证券代码：300601 | 证券简称：康泰生物 公告编号：2025-049 | | --- | --- | | 债券代码：123119 | 债券简称：康泰转 2 | 债券代码：123119 债券简称：康泰转 2 深圳康泰生物制品股份有限公司 2024 年度股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 特别提示： 1、本次股东大会无增加、变更、否决议案的情况； 2、本次股东大会未涉及变更以往股东大会决议的情况； 3、本次股东大会采取现场投票、网络投票相结合的方式召开。 一、会议召开情况 深圳康泰生物制品股份有限公司（以下简称"公司"）2024年度股东大会 以现场投票和网络投票相结合的方式召开。现场会议于2025年5月20日（星期 二）下午14:30在公司会议室召开。 网络投票时间：通过深圳证券交易所交易系统进行网络投票的时间为2025 年5月20日（星期二）9:15-9:25、9:30-11:30和13:00-15:00； 通过深圳证券交易所互联网投票系统进行投票的具体时间为2025年5月20日 （星期二）9:15-15:00。 本次会议 ...

Market Performance - The market rebounded last week, with the China Securities Xinhua National Brand Index rising by 0.94% to 1666.03 points [1] - The Shanghai Composite Index increased by 0.76%, the Shenzhen Component Index by 0.52%, the ChiNext Index by 1.38%, and the CSI 300 Index by 1.12% [1] Strong Stock Performances - Notable strong performers in the brand index included BGI Genomics, which rose by 17.27%, and Yiling Pharmaceutical, which increased by 9.81% [1] - Other significant gainers included Stone Technology and Marubi Biological, which rose by 7.18% and 6.79%, respectively [1] Year-to-Date Stock Gains - Since the beginning of 2025, Marubi Biological has surged by 60.82%, leading the gains, followed by Shanghai Jahwa with a 46.72% increase and BGI Genomics with a 34.45% rise [2] - Other stocks with notable increases include Anji Technology, Xintai, and Weir Shares, each rising over 20% [2] Market Outlook - Institutions expect the market to refocus on domestic economic fundamentals, with a positive policy response anticipated [2][3] - The current market is viewed as being in a high cost-performance range, with significant policy support expected to stabilize the economy and market [2] Economic Data Focus - Attention is drawn to upcoming economic data, particularly export performance and the sustainability of the export supply chain recovery [3] - The prevailing market conditions are supported by policy measures and liquidity easing, which are expected to bolster the stability of the domestic economy and capital markets [3]

Core Viewpoint - The disease prevention and control industry in China is experiencing growth due to increased public awareness, government funding, and advancements in biotechnology and data analysis, leading to improved efficiency in disease management [1][13]. Summary by Sections Industry Overview - Disease prevention and control is a crucial part of public health, focusing on reducing the occurrence and spread of diseases through scientific methods [3]. - Effective disease control can lower healthcare costs, enhance quality of life, and support economic stability [3]. Industry Development - The scale of China's disease prevention and control industry has been on the rise, with central government funding for disease control projects increasing from 17.526 billion to 20.38 billion from 2020 to 2022, followed by a projected recovery to 20.881 billion in 2024, marking an 18.06% year-on-year increase [1][13]. - The number of disease control centers in China has grown from 3,376 in 2021 to 3,429 in 2024, enhancing public health emergency management capabilities [11]. Policy Initiatives - Recent policies emphasize strengthening disease control institutions, enhancing core functions, and promoting scientific research and public health cooperation [5][7]. - The 2024-2025 National Disease Prevention and Control Action Plan encourages local institutions to engage in applied research and technology transfer [5][7]. Competitive Landscape - The disease prevention market in China is competitive, with key players including Fosun Pharma, Kangtai Biological, and Zhifei Biological, which are focusing on innovation and service quality to capture market share [15][19]. Industry Trends - The chronic disease management market is expected to grow significantly due to the aging population and increasing prevalence of chronic diseases, which currently account for 88% of total deaths in China [21]. - Technological innovations such as big data, AI, and IoT are set to transform disease prevention and control, enhancing monitoring and decision-making processes [22]. - The integration of sports and health ("body-health integration") is emerging as a new trend, promoting physical activity as a preventive measure against chronic diseases [23].

| 证券代码：300601 | 证券简称：康泰生物 | 公告编号：2025-048 | | --- | --- | --- | | 债券代码：123119 | 债券简称：康泰转 2 | | 深圳康泰生物制品股份有限公司 关于更换持续督导保荐代表人的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 深圳康泰生物制品股份有限公司（以下简称"公司"）于近日收到中信建投 证券股份有限公司（以下简称"中信建投证券"）出具的《关于更换深圳康泰生 物制品股份有限公司向不特定对象发行可转换公司债券持续督导保荐代表人的 函》。 中信建投证券作为公司 2021 年向不特定对象发行可转换公司债券的保荐机 构，原指派龙舟先生、徐兴文先生担任公司 2021 年向不特定对象发行可转换公 司债券的保荐代表人。龙舟先生现因个人工作变动原因不再担任公司 2021 年向 不特定对象发行可转换公司债券持续督导保荐代表人。鉴于公司于 2025 年仍存 在使用募集资金的情形，中信建投证券仍需继续履行与募集资金的使用和管理相 关的持续督导责任。为保证持续督导工作有序开展，中信建投证券决定委派保荐 代 ...

Investment Rating - The report does not explicitly state an investment rating for the vaccine industry Core Insights - The overall trend in the vaccine industry shows a decline in batch approvals for most vaccine types in Q1 2025, with some exceptions showing recovery or growth in demand [7][29][46] Summary by Category Multi-Component Vaccines - In Q1 2025, multi-component vaccines saw a total of 17 batch approvals, a decrease of 26% compared to the previous year [11][15] - The five-component vaccine maintained its batch approval at 17, while the four-component vaccine had no approvals [15][12] Pneumonia Vaccines - Total batch approvals for pneumonia vaccines in Q1 2025 were 23, down 30% year-on-year [19][21] - The 13-valent pneumonia vaccine had 19 approvals, remaining stable, while the 23-valent vaccine saw a significant drop to 4 approvals, down 71% [24][19] HPV Vaccines - HPV vaccine approvals increased to 57 batches in Q1 2025, a growth of 63% [29][27] - The two-valent HPV vaccine saw a remarkable increase of 367%, with all approvals coming from Wantai Biological Pharmacy [29][32] Influenza Vaccines - Influenza vaccine approvals totaled 29 batches, a significant increase of 263% year-on-year [34][38] - The three-valent influenza vaccine had 28 approvals, while the four-valent vaccine had only 1 approval, down 67% [38][41] Rabies Vaccines - Batch approvals for rabies vaccines increased to 223 in Q1 2025, a growth of 37% [46][48] - The freeze-dried rabies vaccine accounted for the majority of approvals, with Chengda Biological achieving 105 approvals, a 110% increase [48][46] Varicella Vaccines - Varicella vaccine approvals slightly decreased to 83 batches, down 2% [53][54] - The largest contributor was Baike Biological, with 33 approvals, marking a 38% increase [54][53] Hib Vaccines - Hib vaccine approvals fell to 7 batches, a decrease of 50% [59][58] EV71 Vaccines - EV71 vaccine approvals continued to decline, with only 4 batches approved, down 69% [64][63] Rotavirus Vaccines - Rotavirus vaccine approvals totaled 21 batches, a decrease of 46% [68][67] DTP Vaccines - DTP vaccine approvals increased to 18 batches, a growth of 167% [72][73] Meningitis Vaccines - Meningitis vaccine approvals totaled 85 batches, down 34% [78][79] - The AC polysaccharide vaccine accounted for 55 approvals, a decrease of 47% [84][79] Hepatitis B Vaccines - Hepatitis B vaccine approvals increased to 87 batches, a growth of 28% [91][90] IPV Vaccines - IPV vaccine approvals totaled 22 batches, a decrease of 33% [93][92]